EcoDrugPlus

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSGACG00000000113
Gene Symbol: PSMB8A
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSGACG00000000146
Gene Symbol: PSMB8A
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSGACG00000000127
Gene Symbol: PSMB8A
2 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSGACG00000000140
Gene Symbol: PSMB8A
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSGACG00000000118
Gene Symbol: PSMB8A
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSGACG00000000107
Gene Symbol: PSMB9A
1 Cross references
206 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSGACG00000000129
Gene Symbol: PSMB9A
1 Cross references
206 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSGACG00000000137
Gene Symbol: PSMB9A
1 Cross references
206 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSGACG00000000143
Gene Symbol: PSMB9A
1 Cross references
206 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSGACG00000000147
Gene Symbol: PSMB9A
1 Cross references
206 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSGACG00000000212
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1a

Ensembl ID : ENSGACG00000005162
Gene Symbol: PSMC1A
1 Cross references
318 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).